This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): vandetanib, AZD6474, ZD6474, Zactima, Zictifa
Description: Zactima (Vandetanib) is a potent tyrosine kinase inhibitor that blocks several signaling pathways. It inhibits vascular endothelial growth factor receptor 2 (VEGFR2), which blocks the development of tumor blood supply andthe epidermal growth factor receptor (EGFR), which may lead todirect inhibition of cancer cell growth and survival. Vandetanib alsoinhibits RET kinase activity which may be important to the growth anddevelopment of certain tumors.
Genzyme and AstraZeneca
In July 2015, Genzyme, a Sanofi company, entered into a definitive agreement with AstraZeneca to acquire Caprelsa (vandetanib). Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300 million, including an upfront payment of $165 million to acquire the global rights to sell and further develop Caprelsa, and further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities.
In November 2015, AstraZeneca announced that, in the third quarter 2015, the Company completed an agreement with Genzyme for the divestment of Caprelsa (vandetanib).
Partners: AstraZeneca PLC
Additional information available to subscribers only: